Background: Background: The Sino-Nasal Outcome is widely used to assess symptom severity and quality of life for chronic rhinosinusitis patients. No translated version of the tool is available for the study and care of Estonian patients.
Introduction
Rhinosinusitis is defined as an inflammation of the nose and the paranasal sinuses and is characterized by two or more cardinal symptoms. For patients to receive a diagnosis of chronic rhinosinusitis (CRS), symptoms must persist for over 12 weeks and be supported by endoscopy and/or CT-based objective findings (1) .
CRS represents a significant health problem with a substantial socioeconomic burden (2) and effect on quality of life, comparable to that of other chronic diseases like chronic heart disease, chronic obstructive pulmonary disease and chronic backpain (3) .
The exact prevalence of the disease presently remains unknown owing to differences in the study methods and diagnostic criteria employed by different groups. Previous studies and surveys suggest that the prevalence stands at 14-16% in the US (4, 5) and 6.9-27.1% in Europe (6) .
The Sino-nasal Outcome Test 22 (SNOT-22) is a widely used and validated patient-reported measure of chronic rhinosinusitisrelated symptom severity and health-related quality of life (7) .
The SNOT-22 itself is a modified version of the SNOT-20 (8) . The SNOT-22 consists of 22 individual items (score range of 0-5) with Abbreviations: CRS, chronic rhinosinusitis; EPOS, European Position Paper on Rhinosinusitis and Nasal Polyps; SNOT-22, The Sino-Nasal Outcome Test the total score ranging from 0-110. The items cover both the functional and psychological aspects of the disease. The SNOT-22 has been translated into several languages, including French, Lithuanian, Danish and Czech (9) (10) (11) (12) and been appropriately validated. Currently, no Estonian version of the questionnaire exists.
Therefore, the aim of this study was to translate the SNOT-22 to Estonian and validate it using standard procedures described elsewhere (13) . 
Materials and Methods

Validation
This study enrolled 50 patients who had been diagnosed with CRS with or without polyps and 25 healthy volunteers. Pre-test analyses using SNOT-22 scores previously reported in the literature were used to estimate the required sample size. All patients were diagnosed in accordance with the EPOS criteria (1) 
Statistical analysis
All statistical analyses were performed using the SPSS software package (IBM SPSS Statistics for Windows, Version 22; IBM Corp.).
Data was checked for normal distribution and subsequent tests were appropriately selected. We evaluated three main aspects to validate the questionnaire; these are detailed below.
Internal consistency
Internal consistency measures whether different items in a questionnaire that address the same issue correlate with each other and yield similar scores. Cronbach's alpha was used to evaluate internal consistency in the CRS group.
Test-retest reliability
Test-retest reliability reflects the stability of responses and scores over a period of time within which treatment remains unchanged and no symptom changes are expected. Here, we assessed it by correlating matched responses between the initial and re-test.
Validity
Overall mean scores were subjected to the independent t-test to check if the questionnaire could reliably differentiate between healthy volunteers and CRS patients.
Results
The Estonian version of the SNOT-22 is depicted in Figure 1 Table 1 .
Mean SNOT-22 scores significantly differed between CRS patients (41.98, SD ±16.7) and healthy controls (13.08, SD ±9.2), indicating the validity of the translated questionnaire (p < 0.0001).
Thirteen patients were excluded from the re-test; therefore, matched (initial and re-test) responses were available for 37 patients. The mean test-retest time interval was 16.3 days (SD ±3.7). No significant difference (p = 0.302) was observed between the mean SNOT-22 score recorded at the initial test (41.98, SD ±16.7, range 10-77) and that recorded at the retest (38.97, SD ±9.2, range 9-76). A significant positive correlation (r = 0.931, p < 0.0001) was observed between the initial-and re-test mean scores, indicating response stability over time.
Cronbach's alpha was 0.87 and 0.90 for the initial and repeat tests, respectively, underscoring its good internal consistency.
Discussion
The SNOT-22 is a frequently used tool within both clinical and academic settings. Thus far, using it to evaluate symptom severity and health-related quality of life within Estonian CRS populations was not possible. The present study therefore aimed to address this and make a validated and translated Estonian version of the questionnaire available for wider use. Here, we report on the successful translation and adaption of the questionnaire using standardized methods. The Estonian version of SNOT-22 proved to be valid, reliable and stable. The statistical values obtained here (e.g. internal consistency and stability) are comparable to those obtained during the validation of the original questionnaire (7) .
One of the limitations of our study was a relatively small sample size. However, given the statistical power analysis results and that the SNOT-22 has already been successfully validated and adapted several times, we believe that this is unlikely to have had a significant effect on the results reported here. Further, the present study is particularly robust given that it was prospec-tively designed, and all diagnoses were confirmed by experts using the EPOS criteria.
Conclusion
In summary, the present study demonstrates that the Estonian version of the SNOT-22 has good internal consistency, stability and validity and is meaningful for the Estonian population.
The questionnaire was well-received by patients and could be completed without any interviewer assistance or additional instructions. The translated version is therefore a critical addition to the currently available clinical and academic repertoire for the study of rhinological conditions in Estonia. 
